HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease.

Abstract
Detailed liver function test analysis is reported for 30 patients with Alzheimer's disease who were treated with tetrahydroaminoacridine. Results show that a benign elevation of aspartate transaminase occurs in up to 50% cases, that the reaction can be a symptomatic one and that clinical hepatitis can occasionally result. Liver function test changes appear dose-dependent and normalize within 2-4 weeks of stopping the drug or of reducing the dose. Women appear more likely to develop hepatotoxicity than men. Rechallenge with THA in patients previously showing abnormalities in liver function shows that some patients are able to tolerate the drug a second time.
AuthorsJ T O'Brien, S Eagger, R Levy
JournalAge and ageing (Age Ageing) Vol. 20 Issue 2 Pg. 129-31 (Mar 1991) ISSN: 0002-0729 [Print] England
PMID2053502 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Tacrine
Topics
  • Aged
  • Alzheimer Disease (drug therapy, physiopathology)
  • Double-Blind Method
  • Female
  • Humans
  • Liver (drug effects, enzymology, physiopathology)
  • Liver Function Tests
  • Male
  • Middle Aged
  • Tacrine (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: